US FDA's New Paragraph IV Data Further Illustrates Generic Competition Problems
Data on the number of ANDAs submitted with valid paragraph IV certifications shows some products with strong generic interest and others with almost none.
You may also be interested in...
Senate and House will likely have to reconcile differences on drug pricing legislation as Senate HELP Committee seeks public comment on a discussion draft.
US FDA offers best practices and tips to ensure successful meetings, although few have been conducted so far.
AAM's Chip Davis said a user fee cut is not in order, but industry consolidation and product launch problems may mean it cannot accept another large increase.